Progress in the research of immunotherapy‑related hyperprogression (Review).
hyperprogression
immune checkpoint inhibitors
immune microenvironment
macrophage
tumor
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
21
02
2023
accepted:
02
11
2023
medline:
15
1
2024
pubmed:
15
1
2024
entrez:
15
1
2024
Statut:
epublish
Résumé
Immunotherapy has become an effective method for the treatment of a variety of malignant tumors. However, with the development of immunotherapy, the phenomenon of hyperprogression in patients with cancer has gradually attracted attention. Hyperprogression refers to a condition in which the progression of a disease during treatment of a patient with cancer is suddenly accelerated. To date, no reliable marker has been found to predict accelerated tumor growth during immune checkpoint inhibitor (ICI) treatment. The aim the present study was to summarize the definition of hyperprogression and the difference between hyperprogression and pseudocytosis, and investigate the potential mechanisms of hyperprogression including clinical characteristics, potential molecular markers and the immune microenvironment. The effect of macrophage-related different types and factors on tumors in the immune microenvironment was analyzed, and the findings may be used to determine the future directions of research in hyperprogression.
Identifiants
pubmed: 38223402
doi: 10.3892/mco.2023.2701
pii: MCO-20-1-02701
pmc: PMC10784782
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3Informations de copyright
Copyright © 2023, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.